RxDoctor Payments Data

Joseph Hofmeister, MD

Hematology & Oncology · Columbus, OHNPI 1710983002

Payments from drug & device makers

$1,337in general payments, 2019–2025

Across 17 payments — averaging $78.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tempus AI, Inc$525
  • Lilly USA, LLC$206
  • Cardinal Health 110 LLC$176
  • Seagen Inc.$114
  • Amgen$112
  • Mckesson Specialty Care Distribution, LLC$101
  • plus $103 from 4 others

What the payments were for

  • Food & beverage$1,10483%
  • Education$23317%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Tempus AI, Inc6$525
Lilly USA, LLC2$206
Cardinal Health 110 LLC1$176
Seagen Inc.1$114
Amgen1$112
Mckesson Specialty Care Distribution, LLC2$101
Beigene USA, Inc.1$50
Daiichi Sankyo Inc.1$26
Eisai Inc.1$15
Karyopharm Therapeutics Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,337 in reported general payments places this provider in the 30th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$976,372
Medicare patients
309
Services billed
79,992

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PomalystPomalidomide15$345,056
AlecensaAlectinib Hcl11$213,390
ErleadaApalutamide11$168,961
EliquisApixaban154$125,115
XareltoRivaroxaban17$20,478
Abiraterone Acetate12$11,292
Oxycodone Hcl34$1,070
Hydroxyurea37$918
Letrozole32$852
Albuterol Sulfate HfaAlbuterol Sulfate14$602
Gabapentin27$441
Potassium Chloride19$425
Dexamethasone25$394
Mycophenolate Mofetil14$358
Acyclovir26$302

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlanzapine$206$11614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →